CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight

News provided by

Apr 15, 2024, 17:31 ET

The emerging pipeline of CAR-T in NHL includes late-stage, mid-stage, and early-stage drugs in different lines of therapies and different indications, mainly including B- cell Lymphoma such as DLBCL, FL, MCL, MZL, CLL/SLL, and others, with one of them being developed for a T-cell Lymphoma, PTCL.

LAS VEGAS, April 15, 2024 /PRNewswire/ -- DelveInsight's CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Insights report includes a comprehensive understanding of current treatment practices, CAR T-Cell Therapy for NHL emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan].

Key Takeaways from the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Report

According to DelveInsight's analysis, the market size for CAR T-Cell therapy for NHL reached USD 1,200 million in 2023 across the US.
DelveInsight's analysis reveals that the total incident cases of selected indications for CAR-T in NHL in the 7MM comprised ~155,200 in 2023.
Leading CAR T-Cell therapy for NHL companies such as Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Mustang Bio, CRISPR Therapeutics, 2seventy Bio, Imugene, and others are developing novel CAR T-Cell therapies for NHL drugs that can be available in the CAR T-Cell therapy for NHL market in the coming years.
Other promising CAR T-Cell therapies for NHL in the pipeline include Cemacabtagene Ansegedleucel, Rapcabtagene Autoleucel, Zamtocabtagene Autoleucel, MB-106, CTX110, BBT369, Azercabtagene Zapreleucel, and others.
BREYANZI is poised to dominate the CAR-T market in NHL in the forthcoming years, with potential approvals anticipated across two indications: CLL/SLL, follicular lymphoma and MCL. Notably, it has already secured approval for DLBCL in 3L+, 2L+ TE, and NTE.
Novartis is progressing with its additional CD-19 CAR-T therapy, Rapcabtagene autoleucel, with expectations of a significantly reduced turnaround time for availability compared to KYMRIAH.
Companies are leveraging the strength of dual and triple targeting in CAR-T therapies. Miltenyi Biomedicine, ImmPACT Bio, 2seventy bio, and Novartis are developing CD19/20 Bispecific CAR-T, CD79a/CD20 Bispecific CAR-T, and CD2xCD3xCD19 CAR-T, enhancing treatment efficacy by targeting multiple antigens simultaneously.

Discover which therapies are expected to grab the major CAR T-Cell therapy for NHL market share @ CAR T-Cell Therapy for NHL Market Report

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Overview

CAR-T cell therapy represents a groundbreaking advancement in cancer immunotherapy, especially for specific types of NHL that have shown resistance to traditional therapies. Through the manipulation of genetically modified T cells, this state-of-the-art treatment boosts the immune system's capacity to locate and eliminate cancerous cells. Essentially, CAR-T cell therapy modifies a patient's T cells genetically to carry chimeric antigen receptors (CARs) on their surface. These engineered CARs are tailored to identify and attach to particular proteins found on cancer cells' surfaces, thereby directing the immune system to effectively combat the malignancy.

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Epidemiology Segmentation

In 2023, DLBCL had the highest number of cases among all selected indications for CAR-T therapy, followed by Follicular lymphoma. The total incident cases of MZL in the 7MM were around 13,800 in 2023 and are projected to increase during the forecasted period.

The CAR T-Cell therapy for NHL market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Incident Cases of Selected Indications for CAR-T in NHL (Mantle cell lymphoma, DLBCL, Follicular lymphoma, Marginal Zone Lymphoma, Primary mediastinal large B-cell lymphoma, Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma) and Total Indication-wise Eligible Cases of CAR-T in NHL.

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Treatment Market

The treatment landscape for NHL is complex, influenced by factors such as the type of NHL, the stage of the disease, the patient's overall health, and their preferences. CAR-T cell therapy has emerged as a promising option within this landscape, especially for aggressive B-cell NHLs that have not responded to standard treatments. Previously, such cases posed significant challenges, often resulting in poor outlooks despite attempts with salvage chemotherapy and autologous stem cell transplants.

However, the introduction of CAR-T cell therapy has drastically changed this scenario, showing impressive response rates and the potential for long-lasting remissions even in patients with advanced disease after multiple prior treatments. The approval of various CAR-T therapies for NHL by the FDA highlights the importance of this advancement. YESCARTA, KYMRIAH, BREYANZI, and TECARTUS have all proven effective across different types of NHL, including DLBCL, follicular lymphoma, and mantle cell lymphoma.

Ongoing research aims to improve CAR-T cell therapy for NHL further, seeking to increase effectiveness, decrease side effects, and expand the range of target antigens beyond CD19. Additionally, studies are looking into the combined use of CAR-T cell therapy with other treatments like checkpoint inhibitors or targeted therapies, with the ultimate goal of optimizing treatment outcomes for NHL patients.

To know more about CAR T-Cell therapy for Non-Hodgkin's Lymphoma treatment guidelines, visit @ CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Management

Emerging CAR T-Cell Therapies for NHL and Key Companies

Cemacabtagene Ansegedleucel: Allogene Therapeutics
Rapcabtagene Autoleucel: Novartis
Zamtocabtagene Autoleucel: Miltenyi Biomedicine
MB-106: Mustang Bio
CTX110: CRISPR Therapeutics
BBT369: 2seventy Bio
Azercabtagene Zapreleucel: Imugene

Learn more about the FDA-approved CAR T-Cell therapy for NHL @ Drugs for CAR T-Cell Therapy for NHL Treatment

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Dynamics

The dynamics of the CAR T-Cell therapy for the NHL market are expected to change in the coming years. The market for CAR T-cell therapy in NHL is characterized by a surge in research and development activities, as pharmaceutical companies race to bring new therapies to the market. With several CAR T-cell therapies receiving FDA approval, competition among manufacturers is intense, driving innovation and investment in the field. As a result, we witness a dynamic landscape with ongoing clinical trials, collaborations, and strategic partnerships aiming to expand the reach and efficacy of CAR T-cell therapies for NHL.

Moreover, the market dynamics of CAR T-cell therapy for NHL are influenced by patient accessibility and reimbursement challenges. Despite the remarkable efficacy of these therapies, their high cost poses a significant barrier to widespread adoption. Healthcare systems and insurers grapple with the economic implications of CAR T-cell therapy, leading to negotiations on pricing and reimbursement models. Efforts are underway to make these life-saving treatments more accessible to patients, including discussions on value-based pricing and outcome-based reimbursement. As the field continues to evolve, the CAR T-cell therapy for NHL market dynamics will be shaped by a delicate balance between the clinical benefits of CAR T-cell therapy and the economic considerations surrounding its widespread implementation in the treatment of Non-Hodgkin's lymphoma.

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Report Metrics	Details
Study Period	2019–2032
Coverage	7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market CAGR	~15%
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Size in 2023	USD 1,200 Million
Key CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Companies	Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Mustang Bio, CRISPR Therapeutics, 2seventy Bio, Imugene, and others
Key CAR T-Cell Therapy for Non-Hodgkin's Lymphoma in Pipeline	Cemacabtagene Ansegedleucel, Rapcabtagene Autoleucel, Zamtocabtagene Autoleucel, MB-106, CTX110, BBT369, Azercabtagene Zapreleucel, and others

Scope of the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Report

Therapeutic Assessment: CAR T-Cell Therapy for Non-Hodgkin's Lymphoma current marketed and emerging therapies
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Dynamics: Key Market Forecast Assumptions of Emerging CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Drugs and Market Outlook
Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Access and Reimbursement

Discover more about CAR T-Cell therapy for NHL drugs in development @ CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Clinical Trials

Table of Contents

1	KEY INSIGHTS
2	REPORT INTRODUCTION
3	EXECUTIVE SUMMARY OF CAR-T IN NHL
4	KEY EVENTS
5	EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY
6	CAR-T IN NHL MARKET OVERVIEW AT A GLANCE IN THE 7MM
6.1	MARKET SHARE (%) DISTRIBUTION BY INDICATIONS IN 2019
6.2	MARKET SHARE (%) DISTRIBUTION BY INDICATIONS IN 2032
6.3	MARKET SHARE (%) DISTRIBUTION BY THERAPIES IN 2019
6.4	MARKET SHARE (%) DISTRIBUTION BY THERAPIES IN 2032
7	DISEASE BACKGROUND AND OVERVIEW
7.1	INTRODUCTION
7.2	UNDERSTANDING LYMPHOMA
7.2.1	Types of Lymphoma
7.2.2	Types of NHL
7.2.2.1	Subtypes of B-cell lymphoma
7.2.2.2	Subtypes of T-cell and NK-cell lymphoma
7.3	SIGNS AND SYMPTOMS
7.4	STAGING
7.5	DIAGNOSIS OF NHL
8	TREATMENT
8.1	TREATMENT OF INDOLENT NON-HODGKIN LYMPHOMA
8.2	TREATMENT OF AGGRESSIVE NON-HODGKIN LYMPHOMA
8.3	CAR-T CELL THERAPIES: A NEW HOPE
8.3.1	CAR-T Structure
8.3.2	Antigen Selection
8.3.3	Manufacture and Delivery
8.4	CURRENTLY APPROVED CAR T-CELL THERAPY IN NHL
8.4.1	CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma
8.4.1.1	Novel CARs
8.4.2	CAR T-Cell Therapy in Follicular Lymphoma
8.4.3	CAR T-Cell Therapy in Mantle Cell Lymphoma
8.5	LIMITATIONS OF CAR T-CELL THERAPY
8.6	FUTURE DIRECTIONS
8.7	CONCLUSION
9	TREATMENT GUIDELINES
9.1	NCCN GUIDELINES FOR DIFFUSE LARGE B-CELL LYMPHOMA
9.2	NCCN GUIDELINES FOR FOLLICULAR LYMPHOMA
10	EPIDEMIOLOGY AND PATIENT POPULATION
10.1	KEY FINDINGS
10.2	ASSUMPTIONS AND RATIONALE
10.3	EPIDEMIOLOGY SCENARIO IN THE 7MM
10.3.1	Total Incident Cases of Selected Indications for CAR-T in NHL in the 7MM
10.3.2	Total Indication wise Eligible Cases of CAR-T in NHL in the 7MM
11	PATIENT JOURNEY
11.1	DESCRIPTION
12	MARKETED DRUGS
12.1	KEY COMPETITORS
12.2	YESCARTA (AXICABTAGENE CILOLEUCEL): GILEAD SCIENCES (KITE PHARMA)
12.2.1	Product Description
12.2.2	Regulatory Milestones
12.2.3	Other Developmental Activities
12.2.4	Clinical Development
12.2.4.1	Clinical Trial Information
12.2.5	Safety and Efficacy
12.2.6	Product Profile
12.3	KYMRIAH (TISAGENLECLEUCEL): NOVARTIS
12.3.1	Product Description
12.3.2	Regulatory Milestones
12.3.3	Clinical Development
12.3.3.1	Clinical Trial Information
12.3.4	Safety and Efficacy
12.3.5	Product Profile
12.4	BREYANZI (LISOCABTAGENE MARALEUCEL): BRISTOL MYERS SQUIBB
12.4.1	Product Description
12.4.2	Regulatory Milestones
12.4.3	Other Developmental Activities
12.4.4	Clinical Development
12.4.4.1	Clinical Trial Information
12.4.5	Safety and Efficacy
12.4.6	Product Profile
12.5	TECARTUS (BREXUCABTAGENE AUTOLEUCEL): GILEAD SCIENCES (KITE PHARMA)
12.5.1	Product Description
12.5.2	Regulatory Milestones
12.5.2.1	Clinical Trial Information
12.5.3	Safety and Efficacy
12.5.4	Product Profile
13	EMERGING DRUGS
13.1	KEY CROSS
13.2	CEMACABTAGENE ANSEGEDLEUCEL: ALLOGENE THERAPEUTICS
13.2.1	Product Description
13.2.2	Other Developmental Activities
13.2.3	Clinical Development
13.2.3.1	Clinical Trial Information
13.2.4	Safety and Efficacy
13.3	RAPCABTAGENE AUTOLEUCEL: NOVARTIS
13.3.1	Product Description
13.3.2	Clinical Development
13.3.2.1	Clinical Trial Information
13.3.3	Safety and Efficacy
13.4	ZAMTOCABTAGENE AUTOLEUCEL: MILTENYI BIOMEDICINE
13.4.1	Product Description
13.4.2	Other Developmental Activities
13.4.3	Clinical Development
13.4.3.1	Clinical Trial Information
13.4.4	Safety and Efficacy
13.5	MB-106: MUSTANG BIO
13.5.1	Product Description
13.5.2	Other Developmental Activities
13.5.3	Clinical Development
13.5.3.1	Clinical Trial Information
13.5.4	Safety and Efficacy
13.6	CTX110: CRISPR THERAPEUTICS
13.6.1	Product Description
13.6.2	Other Developmental Activities
13.6.3	Clinical Development
13.6.3.1	Clinical Trial Information
13.6.4	Safety and Efficacy
13.7	BBT369: 2SEVENTY BIO
13.7.1	Product Description
13.7.2	Other Developmental Activities
13.7.3	Clinical Development
13.7.3.1	Clinical Trial Information
13.7.4	Safety and Efficacy
13.8	AZERCABTAGENE ZAPRELEUCEL: IMUGENE
13.8.1	Product Description
13.8.2	Other Developmental Activities
13.8.3	Clinical Development
13.8.3.1	Clinical Trial Information
13.8.4	Safety and Efficacy
14	CAR-T IN NHL: MARKET ANALYSIS
14.1	KEY FINDINGS
14.2	MARKET OUTLOOK
14.3	CONJOINT ANALYSIS
14.4	KEY MARKET FORECAST ASSUMPTIONS
14.5	TOTAL MARKET SIZE OF CAR-T IN NHL IN THE 7MM
14.6	UNITED STATES MARKET SIZE
14.6.1	Market Size of CAR-T in NHL by Indications in the United States
14.6.2	Market Size of CAR-T in NHL by Therapies in the United States
14.7	EU4 AND THE UK MARKET SIZE
14.7.1	Market Size of CAR-T in NHL by Indications in the United States
14.7.2	Market Size of CAR-T in NHL by Therapies in EU4 and the UK
14.8	JAPAN MARKET SIZE
14.8.1	Market Size of CAR-T in NHL by Indications in Japan
14.8.2	Market Size of CAR-T in NHL by Therapies in Japan
15	UNMET NEEDS
16	SWOT ANALYSIS
17	KOL VIEWS
18	MARKET ACCESS AND REIMBURSEMENT
18.1	UNITED STATES
18.1.1	Center for Medicare and Medicaid Services (CMS)
18.2	EU4 AND THE UK
18.2.1	Germany
18.2.2	France
18.2.3	Italy
18.2.4	Spain
18.2.5	United Kingdom
18.3	JAPAN
18.3.1	MHLW
18.4	MARKET ACCESS AND REIMBURSEMENT OF CAR-T IN NHL
18.4.1	YESCARTA
18.4.2	KYMRIAH
18.4.3	BREYANZI
18.4.4	TECARTUS
19	APPENDIX
19.1	BIBLIOGRAPHY
19.2	REPORT METHODOLOGY
20	DELVEINSIGHT CAPABILITIES
21	DISCLAIMER
22	ABOUT DELVEINSIGHT

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CAR T-Cell therapy for NHL companies, including Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Mustang Bio, CRISPR Therapeutics, 2seventy Bio, Imugene, among others.

CAR T-Cell Therapy Market

CAR T-Cell Therapy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy companies, including CytoAgents, Genentech, Incyte Corporation, Caribou Biosciences, Chimeric Therapeutics, Allogene Therapeutics, Kyverna Therapeutics, iCell Gene Therapeutics, Synthekine, Janssen Research & Development, SecuraBio, ImmPACT Bio, A2 Biotherapeutics, Gracell Biopharmaceuticals, Wugen, Sana Biotechnology, Oncternal Therapeutics, Vor Biopharma, CARsgen Therapeutics, Autolus Limited, Arcellx, Kite, Novartis, Lyell Immunopharma, ImmPACT Bio, Tmunity Therapeutics, Poseida Therapeutics, Precigen, AffyImmune Therapeutics, 2seventy bio, Takeda, Cartesian Therapeutics, Cabaletta Bio, Legend Biotech, Miltenyi Biomedicine, Beam Therapeutics, among others.

CAR T-Cell Therapy Competitive Landscape

CAR T-cell Therapy Competitive Landscape – 2024 report provides comprehensive insights about the pipeline and current landscape, pipeline and marketed drug profiles, and the key CAR T-cell therapy companies, including Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics,Shanghai Unicar-Therapy Bio-medicine Technology, Sinobioway Cell Therapy, Tessa Therapeutics, Wuhan Bio-Raid Biotechnology, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Cellular Biomedicine Group, Chongqing Precision Biotech, Eureka Therapeutics, Formula Pharmaceuticals, Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology, Mustang Bio, MolMed, Aurora BioPharma, Atara Biotherapeutics, Autolus, Bellicum Pharmaceuticals, Kecellitics Biotech Company, Yake Biotechnology, Minerva Biotechnologies, Allogene Therapeutics, PersonGen BioTherapeutics (Suzhou), Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Shanghai GeneChem, Shanghai Longyao Biotechnology, Shenzhen BinDeBio, among others.

CAR T-Cell Therapy for Multiple Myeloma Market

CAR T-Cell Therapy for Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for multiple myeloma companies, including Cartesian Therapeutics, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen Therapeutics, Poseida Therapeutics, Juno Therapeutics, CRISPR Therapeutics, bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Celyad Oncology, Allogene Therapeutics, Gadeta, Nanjing IASO Biotherapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP